**S5 Table: Guidelines with Institute of Medicine Standards (Yes ‘Y’, No ‘N’)**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| IOM Standards | | | | | | | | | | |
| **Guideline** | **1.Establishing transparency** | **2.Management of conflict of**  **interest (COI)** | **3.Guideline development group composition** | **4.Clinical practice guideline systematic review intersection** | **5.Establishing evidence foundation for and rating strength of recommendations** | **6.Articulatoin**  **of recommendation** | **7.External review** | **8.**  **Updating** | **Overall**  **Score/8** | **High**  **Quality** |
| **Osteoporosis Canada 2002** 55**.** | Y | N | N | Y | Y | Y | N | Y | 5 | ✓ |
| **US Preventive Services Task force 2002** 56**.** | Y | Y | N | Y | Y | N | Y | N | 5 | ✓ |
| **Canadian Task Force on Preventive Health Care 2004** 49 | N | N | N | Y | Y | Y | N | N | 3 |  |
| **American University of Beirut Medical Center 2005** 57**.** | N | N | N | Y | Y | Y | N | Y | 4 |  |
| **Guidelines in Asia 2006** 48**.** | N | N | N | N | N | N | N | N | 0 |  |
| **the American College of Physicians guidelines 2008** 58**.** | Y | Y | N | Y | Y | Y | N | N | 5 | ✓ |
| **National Osteoporosis Foundation 2008** 53**.** | N | Y | N | N | N | N | N | Y | 2 |  |
| **First Update of the Lebanese Guidelines 2008** 59**.** | Y | N | N | Y | Y | N | N | Y | 4 |  |
| **Singapore Clinical Guidelines 2009** 60 | Y | N | Y | Y | Y | Y | N | Y | 6 | ✓ |
| **Osteoporosis Canada 2010** 46**.** | Y | N | Y | Y | Y | Y | N | N | 5 | ✓ |
| **American Association of Clinical Endocrinologist AACE 2010** 61 | N | N | N | Y | Y | Y | N | N | 3 |  |
| **The Australien Guidelines 2010** 44 | Y | Y | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| **Guideline** | **1.Establishing transparency** | **2.Management of conflict of**  **interest (COI)** | **3.Guideline development group composition** | **4.Clinical practice guideline systematic review intersection** | **5.Establishing evidence foundation for and rating strength of recommendations** | **6.Articulatoin**  **of recommendation** | **7.External review** | **8.**  **Updating** | **Total**  **Score/8** | **High**  **Quality** |
| **South Africa guidelines 2010** 62 | Y | N | Y | Y | Y | Y | N | N | 5 | ✓ |
| **Greece National Medicine Agency 2011** 63 | N | N | N | N | N | N | N | N | 0 |  |
| **USPSTF 2011** 64 | Y | Y | N | Y | Y | Y | Y | N | 6 | ✓ |
| **University of Michigan Health System Guideline 2011** 65 | Y | Y | N | Y | N | Y | Y | N | 5 | ✓ |
| **Taiwan osteoporosis practice guidelines 2011** 66**.** | Y | Y | N | Y | Y | Y | Y | Y | 7 | ✓ |
| **British Columbia Medical Association 2012** 50**.** | Y | Y | Y | N | N | N | N | N | 3 |  |
| **The Malaysian Osteoporosis Society 2012** 67**.** | Y | Y | N | Y | Y | Y | Y | Y | 7 | ✓ |
| **NICE guidelines 2012** 9 | Y | Y | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| **The Endocrine Society 2012** 68 | Y | Y | N | N | Y | Y | Y | N | 5 |  |
| **Institute for Clinical System Improvement guideline, 2013** 51**.** | Y | Y | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| **Indian Menopause Society, 2013** 69 | N | N | N | Y | N | N | Y | Y | 3 |  |
| **National Foundation of Osteoporosis**  **2014** 54 | N | Y | N | N | N | N | N | N | 1 |  |
| **the Society of Obstetricians and Gynaecologists of Canada** 70 | N | N | N | N | N | Y | N | N | 1 |  |
| **National Osteoporosis Guideline Group (NOGG)/UK 2014** 71 | N | Y | N | N | N | N | N | Y | 2 |  |
| **The Malaysian Osteoporosis Society guideline, 2015** 72 | Y | Y | N | Y | Y | Y | N | N | 5 | ✓ |
| **Scottish Intercollegiate Guidelines Network (SIGN) guideline, 2015** 52 | Y | Y | Y | Y | Y | Y | Y | Y | 8 | ✓ |
| **2015 Guidelines for Osteoporosis in Saudi Arabia** 73**.** | Y | Y | N | Y | N | N | N | N | 3 |  |
| **National Osteoporosis Guideline Group(NOGG)/UK, 2016** 74**.** | Y | Y | Y | N | Y | Y | Y | Y | 7 |  |
| **Italian Society for Osteoporosis, Mineral metabolism and Bone Diseases (SIOMMMS) 2016** 75 | N | N | N | N | N | N | N | N | 0 |  |
| **Alberta Guidelines 2016** 76 | N | N | N | N | N | N | N | N | 0 |  |
| **American Association of Clinical Endocrinologist AACE 2016** 77 | N | N | N | Y | Y | Y | Y | N | 4 |  |